Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide PK with Coffee and Tea
NCT07044479Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity up to 168 hours, Area Under the Concentration-Time Curve from Time 0 to Last up to 168 hours and 1 more. Started Jul 2025; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07044479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044479.